NASDAQ:CMPI Checkmate Pharmaceuticals (CMPI) Stock Price, News & Analysis → It’s now possible to know the win rate of every trade… BEFORE you take it! (From WealthPress) (Ad) Free CMPI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$10.50▼$10.5050-Day Range$10.37▼$10.5052-Week Range$2.00▼$10.50VolumeN/AAverage Volume142,261 shsMarket Capitalization$231.40 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Checkmate Pharmaceuticals alerts: Email Address Ad DTIHow a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…Click now to see for yourself what $0.25 Cent Trades is all about About Checkmate Pharmaceuticals Stock (NASDAQ:CMPI)Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More Ad DTIHow a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…Click now to see for yourself what $0.25 Cent Trades is all about CMPI Stock News HeadlinesMay 26, 2022 | tmcnet.comUniversity of Iowa Holden Comprehensive Cancer Center PresentsMay 26, 2022 | finance.yahoo.comUniversity of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingApril 28, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.May 18, 2022 | apnews.comINVESTIGATION NOTICE: Halper Sadeh LLP Investigates TVTY, ACC, SWCH, CMPIMay 13, 2022 | seekingalpha.comCheckmate Pharmaceuticals GAAP EPS of -$0.73 beats by $0.02May 13, 2022 | finance.yahoo.comCheckmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business UpdateMay 5, 2022 | apnews.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates NLSN, CMPI, SBOWApril 20, 2022 | msn.comRegeneron (REGN) to Buy Checkmate Pharmaceuticals for $250MApril 28, 2024 | DTI (Ad)My top 100 stocks…We recently ran an internal audit of every trade recommendation I’ve published across all my services… And let me tell ya, we found some incredible insights… For starters, we found about 100 stocks I trade really, really well.April 20, 2022 | barrons.comShareholder Alert: Ademi LLP investigates whether Checkmate Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with RegeneronApril 19, 2022 | bizjournals.comCheckmate stock quadruples on news of Regenerate acquisitionApril 19, 2022 | finance.yahoo.comWhy Checkmate Pharmaceuticals Stock Is Rocketing Higher TodayApril 19, 2022 | stockhouse.comCMPI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Checkmate Pharmaceuticals, Inc. Is Fair to ShareholdersApril 19, 2022 | marketwatch.comCheckmate Pharmaceuticals Shares Take Flight on Regeneron Deal >CMPIApril 8, 2022 | tmcnet.comCheckmate Pharmaceuticals Presents Clinical Trial Biomarker Data withApril 8, 2022 | finance.yahoo.comCheckmate Pharmaceuticals Presents Clinical Trial Biomarker Data with Vidutolimod at the 2022 American Association for Cancer Research (AACR) Annual MeetingMarch 8, 2022 | nz.finance.yahoo.comCheckmate Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual MeetingMarch 8, 2022 | finance.yahoo.comCheckmate Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual MeetingFebruary 10, 2022 | bizjournals.comThe Petri Dish: Syndax, Checkmate get new CEOs; Biogen stays in biosimilars gameFebruary 9, 2022 | seekingalpha.comCheckmate Pharmaceuticals appoints Alan Bash as President, CEOFebruary 9, 2022 | finance.yahoo.comCheckmate Pharmaceuticals Appoints Alan Bash as President and CEOJanuary 31, 2022 | nasdaq.comCheckmate Pharmaceuticals, Inc. Common Stock (CMPI)January 31, 2022 | finance.yahoo.comCheckmate Pharmaceuticals Welcomes Industry Leader Jon Wigginton, M.D. to its Board of DirectorsJanuary 7, 2022 | nasdaq.comHere's Why We're A Bit Worried About Checkmate Pharmaceuticals' (NASDAQ:CMPI) Cash Burn SituationJanuary 3, 2022 | finance.yahoo.comCheckmate Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual ConferenceDecember 20, 2021 | finance.yahoo.comCheckmate Pharmaceuticals Announces Initiation of Patient Dosing in Phase 2 Multi-Indication Trial Using VidutolimodNovember 15, 2021 | finance.yahoo.comCheckmate Pharmaceuticals to Present at the Piper Sandler 33rd Annual Virtual Healthcare ConferenceSee More Headlines Receive CMPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Checkmate Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today4/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CMPI CUSIPN/A CIK1651431 Webwww.checkmatepharma.com Phone617-682-3625FaxN/AEmployees28Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-61,400,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-83.92% Return on Assets-74.99% Debt Debt-to-Equity RatioN/A Current Ratio5.20 Quick Ratio5.20 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.50 per share Price / Book4.20Miscellaneous Outstanding Shares22,038,000Free Float8,242,000Market Cap$231.40 million OptionableNot Optionable Beta-4.81 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Robert F. Dolski (Age 52)CFO & Principal Accounting Officer Comp: $411.7kDr. James E. Wooldridge M.D. (Age 56)Chief Medical Officer Comp: $567.29kMr. Alan Bash (Age 50)Pres, CEO & Director Dr. Arthur M. Krieg M.D. (Age 65)Ph.D., Founder, Chief Scientific Officer, Treasurer, Sec. & Independent Director Ms. Katherine A. Eade (Age 48)Gen. Counsel Dr. Kleem Chaudhary Ph.D. (Age 46)Chief Bus. Officer More ExecutivesKey CompetitorsSutro BiopharmaNASDAQ:STROAdverum BiotechnologiesNASDAQ:ADVMCoherus BioSciencesNASDAQ:CHRSFennec PharmaceuticalsNASDAQ:FENCElevation OncologyNASDAQ:ELEVView All Competitors CMPI Stock Analysis - Frequently Asked Questions How were Checkmate Pharmaceuticals' earnings last quarter? Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) posted its quarterly earnings data on Friday, November, 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.02. What other stocks do shareholders of Checkmate Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Checkmate Pharmaceuticals investors own include Oak Street Health (OSH), Adobe (ADBE), Berkshire Hathaway (BRK.A), Lockheed Martin (LMT), Tesla (TSLA), Acutus Medical (AFIB), BigCommerce (BIGC), Freeline Therapeutics (FRLN), Rocket Companies (RKT) and Agnico Eagle Mines (AEM). When did Checkmate Pharmaceuticals IPO? Checkmate Pharmaceuticals (CMPI) raised $75 million in an IPO on Friday, August 7th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and BTIG was co-manager. This page (NASDAQ:CMPI) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithJeff Bezos Just Humiliated Elon MuskInvestorPlaceThe World's First "$20 Trillion Drug?"Behind the Markets4 Cryptos BETTER than BitcoinTrue Market InsidersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingElon Musk Secret Crypto Plot ExposedCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Checkmate Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
